AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24508899 — intervention group
Group type: COMPARATOR
Intervention: 7-day faropenem treatment
Number of subjects: 200
Study 24508899 — intervention group
Group type: EXPERIMENTAL
Intervention: faropenem
Number of subjects: 200
Study 22953994 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral exercise program (weekly sessions and homework for 6 months)
Number of subjects: 192
Study 22953994 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral exercise program
Number of subjects: 192
Study 22953994 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 192
Study 20699432 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemia (5.5 mmol/l)
Number of subjects: 38
Study 20699432 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive hypoglycemia (3.9-2.5 mmol/l)
Number of subjects: 38
Study 17414808 — intervention group
Group type: COMPARATOR
Intervention: Control (non-vibration condition)
Number of subjects: 20
Study 17414808 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Hz WBV
Number of subjects: 20
Study 17414808 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz WBV
Number of subjects: 20
Study 17414808 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz WBV
Number of subjects: 20
Study 16162749 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission option present (preservation of status quo)
Number of subjects: 125
Study 14707887 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) group
Number of subjects: 988
Study 14707887 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 988
Study 10809469 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 2652
Study 8908222 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg alfentanil (group I, ALF 10)
Number of subjects: 100
Study 8908222 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms/kg alfentanil (group II, ALF 20)
Number of subjects: 100
Study 8908222 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 micrograms/kg sufentanil (group III, SUF 0.25)
Number of subjects: 100
Study 8908222 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg sufentanil (group IV, SUF 0.5)
Number of subjects: 100
Study 1678650 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg intravenously three times a day until the fourth postoperative day (n = 10)
Number of subjects: 20
Study 1678650 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 20
Study 6761063 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 354
Study 6761063 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to surgery
Number of subjects: 354
Study 31831028 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) treatment
Number of subjects: 68
Study 31831028 — intervention group
Group type: COMPARATOR
Intervention: Standard controlled ovarian hyperstimulation with GnRH agonist
Number of subjects: 68
Study 28443489 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intensive lifestyle intervention including supervised training (1-3 hours/day), a healthy hypo-caloric diet (−500 to −700 kCal/day), and education in healthy lifestyle
Number of subjects: 84
Study 25525051 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) inactivated influenza vaccine (IIV)
Number of subjects: 205
Study 25525051 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) inactivated influenza vaccine (IIV)
Number of subjects: 205
Study 21888570 — intervention group
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A
Number of subjects: 25
Study 21888570 — intervention group
Group type: COMPARATOR
Intervention: Onabotulinum toxin A
Number of subjects: 25
Study 20195266 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 738
Study 19126424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadmium exposure
Number of subjects: 0
Study 19126424 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese and iron levels in breast milk
Number of subjects: 0
Study 19126424 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium levels in breast milk
Number of subjects: 0
Study 17328957 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-convulsive therapy (ECT)
Number of subjects: 24
Study 17328957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ECT)
Number of subjects: 24
Study 15504128 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine treatment (62.5 mg/day for <20 kg, 125 mg/day for 20-40 kg, 250 mg/day for >40 kg)
Number of subjects: 26
Study 11223322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acyclovir
Number of subjects: 1792
Study 11223322 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count
Number of subjects: 1792
Study 9339840 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program (16 weeks, 3 days/week, 10 min warm-up, 15-25 min aerobic session at 60-75% VO2 peak, 5 min cool-down)
Number of subjects: 16
Study 9339840 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program
Number of subjects: 16
Study 9339840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic training)
Number of subjects: 16
Study 8279252 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bolus injection of 4 mg morphine in 2 ml volume (Group I)
Number of subjects: 60
Study 8279252 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bolus injection of 4 mg morphine in 10 ml volume (Group II)
Number of subjects: 60
Study 8279252 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bolus injection of 4 mg morphine in 20 ml volume (Group III)
Number of subjects: 60
Study 3722035 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 100
Study 3722035 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside (gentamicin and tobramycin)
Number of subjects: 100
Study 30553429 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude to Work Program (n=229)
Number of subjects: 464
Study 30553429 — intervention group
Group type: COMPARATOR
Intervention: Control condition (written material about safety topics, n=235)
Number of subjects: 464
Study 26786149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyometrial oxytocin at 0.07 IU/kg
Number of subjects: 40
Study 26786149 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin at 0.07 IU/kg
Number of subjects: 40
Study 26786149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24983748 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week low calorie diet followed by a 6-month ad libitum weight-maintenance diet
Number of subjects: 311
Study 24983748 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue CIDEA mRNA levels
Number of subjects: 311
Study 22644026 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 35
Study 22644026 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 35
Study 22644026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine
Number of subjects: 35
Study 20394040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 990
Study 20394040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg twice daily
Number of subjects: 990
Study 20394040 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg initially and then 75 mg once daily
Number of subjects: 990
Study 18156828 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevating prosthesis
Number of subjects: 0
Study 16311295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation with GnRH antagonist co‐treatment and single embryo transfer (SET)
Number of subjects: 391
Study 16311295 — intervention group
Group type: COMPARATOR
Intervention: Conventional GnRH agonist long protocol ovarian stimulation with double embryo transfer (DET)
Number of subjects: 391
Study 12749481 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study 11034885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 14
Study 11034885 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 14
Study 11034885 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-percutan application
Number of subjects: 14
Study 11034885 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 14
Study 9546928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg three times daily
Number of subjects: 3899
Study 9546928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3899
Study 9546928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg three times daily (after excluding patients on potassium-losing diuretics)
Number of subjects: 3899
Study 9546928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after excluding patients on potassium-losing diuretics)
Number of subjects: 3899
Study 9546928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 3899
Study 1449116 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional 5-fluorouracil (5-FU) at 350 mg/m2 per day for 2 weeks with a 2-week rest period on a monthly basis
Number of subjects: 184
Study 1449116 — intervention group
Group type: COMPARATOR
Intervention: Bolus 5-fluorouracil (5-FU) at 400-450 mg/m2 for 5 days every 28 days
Number of subjects: 184
Study 2931840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg twice a day)
Number of subjects: 40
Study 2931840 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg twice a day)
Number of subjects: 40
Study 29808753 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system (RAS) inhibitors
Number of subjects: 1465
Study 29808753 — intervention group
Group type: COMPARATOR
Intervention: No RAS inhibitors (Control)
Number of subjects: 1465
Study 26841258 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 μg/day (s.c. injection)
Number of subjects: 28
Study 26841258 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD)
Number of subjects: 28
Study 26841258 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic Acid (ZOL) 5 mg/year (i.v. infusion)
Number of subjects: 28
Study 25913343 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) intervention
Number of subjects: 0
Study 25913343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23017527 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mirodenafil once daily
Number of subjects: 180
Study 23017527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 19781896 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal prongs (HFNP)
Number of subjects: 50
Study 19781896 — intervention group
Group type: COMPARATOR
Intervention: High-flow face mask (HFFM)
Number of subjects: 50
Study 17973208 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride (Group A; n=17)
Number of subjects: 52
Study 17973208 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride and metformin (Group B; n=18)
Number of subjects: 52
Study 17973208 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin (Group C; n=17)
Number of subjects: 52
Study 17973208 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 52
Study 15772205 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stent at 3.6 weeks after MI
Number of subjects: 26
Study 15772205 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 26
Study 12811273 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (lumbar discectomy)
Number of subjects: 71
Study 10577434 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 3783
Study 10577434 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and socioeconomic factors
Number of subjects: 3783
Study 9414432 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione
Number of subjects: 0
Study 9414432 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (in vitro)
Number of subjects: 0
Study 2065926 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (22 mumol.kg‐1.h‐1)
Number of subjects: 5
Study 2065926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 2065926 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐8 (20 pmol.kg‐1.h‐1) after saline meal (0.154 mol/L)
Number of subjects: 5
Study 2065926 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 5
Study 6807248 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine (N)
Number of subjects: 30
Study 6807248 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/Kg intravenous acebutolol (A)
Number of subjects: 30
Study 6807248 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine (N) and 1 mg/Kg intravenous acebutolol (A)
Number of subjects: 30
Study 30509768 — intervention group
Group type: EXPERIMENTAL
Intervention: It's Your Game: Keep It Real (IYG) program
Number of subjects: 4562
Study 30509768 — intervention group
Group type: COMPARATOR
Intervention: No-IYG
Number of subjects: 4562
Study 27677865 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen nasal spray
Number of subjects: 19
Study 27677865 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of prednisone
Number of subjects: 19
Study 26868306 — intervention group
Group type: EXPERIMENTAL
Intervention: Venofix Safety
Number of subjects: 33
Study 26868306 — intervention group
Group type: EXPERIMENTAL
Intervention: BD Vacutainer Push Button
Number of subjects: 33
Study 26868306 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety-Multifly
Number of subjects: 33
Study 26868306 — intervention group
Group type: EXPERIMENTAL
Intervention: Surshield Surflo
Number of subjects: 33
Study 25122497 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnometry-Assisted Respiratory Training (CART)
Number of subjects: 120
Study 25122497 — intervention group
Group type: COMPARATOR
Intervention: Slow Breathing and Awareness Training (SLOW)
Number of subjects: 120
Study 22039290 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg
Number of subjects: 463
Study 22039290 — intervention group
Group type: COMPARATOR
Intervention: Modafinil 200 mg
Number of subjects: 463
Study 19084450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate (2.5 mg daily)
Number of subjects: 110
Study 19084450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate (20 mg intermittently)
Number of subjects: 110
Study 19084450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate
Number of subjects: 110
Study 19084450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 17907106 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 15191298 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement by five observers
Number of subjects: 22
Study 15191298 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated measurements
Number of subjects: 22
Study 12587688 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 320 mg daily
Number of subjects: 516
Study 12587688 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 640 mg daily
Number of subjects: 516
Study 11425681 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 897
Study 11425681 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 897
Study 9249115 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (F) 100 microg and 200 microg
Number of subjects: 80
Study 9249115 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (S) 20 microg and 30 microg
Number of subjects: 80
Study 9249115 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl (F) 25 microg
Number of subjects: 80
Study 9249115 — intervention group
Group type: COMPARATOR
Intervention: Epidural sufentanil (S) 5 microg
Number of subjects: 80
Study 8287869 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg trimetazidine as an intravenous (i.v.) bolus followed by an infusion of trimetazidine at 60 mg.24 h‐1 for 48 h (n = 69)
Number of subjects: 136
Study 8287869 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (n = 67)
Number of subjects: 136
Study 3788761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (5 to 10 mg/min until >= 95% VPD suppression or total 450 mg, average loading dose 4.4 mg/kg, infusion rate 0.1 mg/kg/min)
Number of subjects: 22
Study 3788761 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1 mg/kg over 3 minutes, with a second bolus if >= 95% suppression not achieved after 10 minutes)
Number of subjects: 22
Study 29788293 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care educational intervention of four sessions lasting 45-60 min augmented with text messages
Number of subjects: 260
Study 29788293 — intervention group
Group type: COMPARATOR
Intervention: Usual education program in health centers
Number of subjects: 260
Study 27093164 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal Junior + RCV (day 1)
Number of subjects: 327
Study 27093164 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal Junior (day 1) + RCV (day 29)
Number of subjects: 327
Study 27093164 — intervention group
Group type: COMPARATOR
Intervention: Havrix 720 + RCV (day 1)
Number of subjects: 327
Study 27093164 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 327
Study 24598584 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate hypertension education sessions (3 sessions led by nurses)
Number of subjects: 146
Study 24598584 — intervention group
Group type: COMPARATOR
Intervention: Usual hypertension care
Number of subjects: 146
Study 24598584 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate hypertension education sessions
Number of subjects: 146
Study 21816888 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 74
Study 21816888 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 74
Study 20435994 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded VTE guidelines developed by the orthopaedic surgical panel
Number of subjects: 0
Study 20435994 — intervention group
Group type: EXPERIMENTAL
Intervention: Review of evidence by the orthopaedic surgical panel
Number of subjects: 0
Study 20435994 — intervention group
Group type: EXPERIMENTAL
Intervention: Contribution of the orthopaedic panel to NICE guidelines
Number of subjects: 0
Study 18245584 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collected on the day of surgery
Number of subjects: 177
Study 18245584 — intervention group
Group type: COMPARATOR
Intervention: Data collected four weeks preoperatively
Number of subjects: 177
Study 18245584 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between ratings provided four weeks preoperatively and on the day of surgery
Number of subjects: 177
Study 15914345 — intervention group
Group type: COMPARATOR
Intervention: Normal fetuses (control group)
Number of subjects: 61
Study 15914345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuses with PCK (Potter's syndrome)
Number of subjects: 61
Study 15914345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetus with PCK (Trisomy 9)
Number of subjects: 61
Study 15914345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuses with hydronephrosis
Number of subjects: 61
Study 12597674 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) training once a week for 4 weeks, practiced at home daily.
Number of subjects: 40
Study 12597674 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) training after 4 weeks.
Number of subjects: 40
Study 12597674 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) training.
Number of subjects: 40
Study 10334425 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg q.d.)
Number of subjects: 20
Study 10334425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8944741 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents approving all referrals (intervention group)
Number of subjects: 254
Study 8944741 — intervention group
Group type: COMPARATOR
Intervention: Residents with no restrictions on appointments (control group)
Number of subjects: 254
Study 1721246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (BK)
Number of subjects: 10
Study 1721246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) after withdrawal of ACE inhibitors
Number of subjects: 10
Study 1721246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 1-7 (BK1-7)
Number of subjects: 10
Study 1721246 — intervention group
Group type: COMPARATOR
Intervention: Cough responses to citric acid
Number of subjects: 10
Study 1721246 — intervention group
Group type: COMPARATOR
Intervention: Substance P (SP)
Number of subjects: 10
Study 30968965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling after resistance exercise
Number of subjects: 17
Study 30968965 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise only
Number of subjects: 17
Study 30650480 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw rhubarbs by intranasal jejuna injection, 100 mL each time, twice per day for 3-7 days
Number of subjects: 84
Study 30650480 — intervention group
Group type: COMPARATOR
Intervention: Routine medication (control group)
Number of subjects: 84
Study 25645174 — intervention group
Group type: EXPERIMENTAL
Intervention: UCS deflation (ABAdefl) with decreasing UCS intensity over time
Number of subjects: 0
Study 25645174 — intervention group
Group type: COMPARATOR
Intervention: Control group (ABActrl) with UCS presentations at equal intensity
Number of subjects: 0
Study 25645174 — intervention group
Group type: COMPARATOR
Intervention: Filler task (ABB)
Number of subjects: 0
Study 25645174 — intervention group
Group type: COMPARATOR
Intervention: Filler task (ABA)
Number of subjects: 0